Background

The rarity of primary cutaneous lymphoma and the diversity in presentation and outcome from nodal lymphoma has led to the development of highly specialized international centers. These centers have developed links through organizations such as the International Society for Cutaneous Lymphomas (ISCL), European Organization of Cutaneous Lymphoma Task Force (EORTC CLTF), United States Cutaneous Lymphoma Consortium (USCLC), Australian Skin Lymphoma Network and UK Cutaneous Lymphoma Group (UK-CLG). Some of these groups have formed clinical trials, translational research and have regular meetings but no Consortium exists to coordinate the areas of development allowing projects to become cohesive and impactful, globally. It has been agreed that a Consortium consisting of board members from all these groups is required if we are to succeed in improving our understanding of the clinical and translational aspects of these rare lymphomas.

After a series of meetings and teleconferences in 2012-2013, the Cutaneous Lymphoma International Consortium (CLIC) has been formed. This is an alliance between; The ISCL, EORTC CLTF, USCLC, Australian Skin Lymphoma Network and UK-CLG. With the shared goal of bringing together an international community to produce meaningful large-sample data in this group of rare lymphomas, these groups have collaborated to establish a machinery to work cohesively, to develop consistent and well-defined goals and endpoints. As an initial priority project, we are developing a prospective study to determine important prognostic markers and treatment responses with the aim of improving clinical outcome in MF and SS. Due to the rarity of this lymphoma only a large collaboration would include sufficient patients to reach statistical significance. Members of these groups have previously worked together to share research results and ideas at two prior World Congresses (Chicago 2010 & Berlin 2013) with a third planned in New York for 2016.